Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

MSLE

Satellos Bioscience Inc

Feb 13 • 04:00PM ET

11.50

+0.23 2.04 %

Healthcare • Biotechnology • Canada • NASD

Held by: SURI

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.57	Insider Own	16.54%	Shs Outstand	15.42M	Perf Week	2.22%
Market Cap	177.79M	Forward P/E	-	EPS next Y	-5.07	Insider Trans	0.00%	Shs Float	12.90M	Perf Month	41.06%
Enterprise Value	143.18M	PEG	-	EPS next Q	-0.21	Inst Own	1.71%	Short Float	-	Perf Quarter	91.67%
Income	-21.94M	P/S	-	EPS this Y	49.63%	Inst Trans	-	Short Ratio	-	Perf Half Y	128.74%
Sales	0.00M	P/B	5.22	EPS next Y	-378.62%	ROA	-79.16%	Short Interest	-	Perf YTD	95.58%
Book/sh	2.20	P/C	5.14	EPS next 5Y	6.14%	ROE	-89.10%	52W High	12.50 -8.00%	Perf Year	86.30%
Cash/sh	2.24	P/FCF	-	EPS past 3/5Y	29.67% 5.62%	ROIC	-64.52%	52W Low	4.53 153.93%	Perf 3Y	178.26%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.64% 9.15%	Perf 5Y	-24.30%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	29.54%	Oper. Margin	-	ATR (14)	0.82	Perf 10Y	118.80%
Dividend Ex-Date	-	Quick Ratio	10.70	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	63.92	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	10.70	EPS Q/Q	40.72%	SMA20	7.04%	Beta	1.20	Target Price	22.08
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	42.77%	Rel Volume	8.90	Prev Close	11.27
Employees	14	LT Debt/Eq	0.00	Earnings	Nov 14 BMO	SMA200	83.46%	Avg Volume	18.26K	Price	11.50
IPO	Feb 19, 2009	Option/Short	No / Yes	EPS/Sales Surpr.	-9.82% -	Trades		Volume	162,488	Change	2.04%

Feb-11-26 08:12AM	Satellos price target raised to $40 from $5 at Oppenheimer (TipRanks) +7.08%
Feb-10-26 07:00AM	Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 (Business Wire)
Feb-09-26 05:00PM	Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters Option to Purchase Additional Shares (Business Wire)
Feb-06-26 08:30AM	Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States (Business Wire) -5.54%

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX and Leveraging MyoReGenX, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki on July 27, 2012 and is headquartered in Toronto, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MSLE

Satellos Bioscience Inc

Upgrade your FINVIZ experience